Foreword–US Respiratory & Pulmonary Diseases. 2019;4(1):6

The topic of the carbon footprint of human activities is one frequently discussed worldwide. There have been conscious efforts across multiple fields, including healthcare, to reduce their carbon footprint. In Canada, 4.6% of greenhouse gases (GHG) are manufactured by the healthcare institutions, ranking it second worldwide. 1,2 The treatments for asthma and chronic obstructive pulmonary disease (COPD) […]

Asthma is a heterogeneous disease with notable variation in its clinical course and response to treatment. Despite management with standard-of-care therapies, a proportion of patients remain uncontrolled and at risk of life-threatening exacerbations and disease worsening. Advances in understanding the heterogeneity of asthma have helped to identify patients who will benefit from an understanding of […]

Welcome to the latest issue of touchREVIEWS in Respiratory & Pulmonary Diseases, in which we bring you a range of topical and timely articles in the field of lung diseases. In this issue, we begin with an expert interview about lebrikizumab (an anti-interleukin-13 biologic) for asthma. Stanley Szefler describes the clinical trials that have helped […]